Coombs Test (Antiglobulin Test): Direct and Indirect DCT/ICT Explained

Key takeaways

• The direct Coombs test looks at the red cells themselves; the indirect Coombs test looks at the plasma.
• A positive Coombs test is not a diagnosis on its own, healthy people and people with infections, autoimmune disease or recent transfusion can test positive without significant haemolysis.
• A negative Coombs test does not exclude haemolysis; some immune haemolytic anaemias are Coombs-negative, and many haemolytic anaemias in India are non-immune (thalassaemia, G6PD deficiency, sickle cell disease).
• The Coombs test does not measure how severe haemolysis is, haemoglobin, reticulocyte count, LDH, bilirubin and haptoglobin do that.
• The Coombs test is a routine venous blood draw and usually takes only a few minutes at the sampling counter.

At a glance

Also known as

• Antiglobulin test: the formal name.
• DCT / DAT: direct Coombs test or direct antiglobulin test.
• ICT / IAT: indirect Coombs test or indirect antiglobulin test.
• Antibody screening: the common laboratory name for the indirect test in transfusion and antenatal work.
• In Indian clinics and antenatal cards, patients often hear "ICT test in pregnancy", "Rh antibody test" or simply "Coombs".

What the Coombs test is

Red cells can be coated by antibodies that the immune system has made against them. These antibodies are too small to make the cells clump on their own. Coombs reagent (anti-human globulin) bridges them, producing visible agglutination.

Direct Coombs test (DCT): the patient's own red cells are washed and mixed with anti-human globulin. Agglutination means antibody or complement is already sitting on the cells inside the body.

Indirect Coombs test (ICT): the patient's plasma or serum is incubated with test red cells of known antigen type. Agglutination means free antibody is circulating that could attack transfused cells or, in pregnancy, cross the placenta.

Laboratories may use tube, gel-card (column agglutination) or solid-phase methods. Sensitivity and grading conventions differ between methods, so results from different laboratories are not always directly comparable.

Why the Coombs test is done

• Suspected immune haemolytic anaemia: anaemia with jaundice, dark urine, a high reticulocyte count or raised LDH.
• Newborn jaundice or anaemia: DCT on cord or neonatal blood where haemolytic disease of the fetus and newborn (HDFN) due to Rh or ABO incompatibility is possible.
• Antenatal care: ICT (antibody screen) in Rh D-negative women, and in others as per obstetric protocol, to detect red cell alloantibodies.
• Before transfusion: the indirect antiglobulin technique underpins antibody screening and crossmatching.
• Suspected transfusion reaction: a post-transfusion DCT helps identify immune destruction of transfused cells.
• Suspected drug-induced immune haemolysis: for example with some cephalosporins, penicillins, methyldopa or piperacillin.

Who should get this test

• People with unexplained anaemia plus features suggesting red cell breakdown, yellowing of eyes, dark or cola-coloured urine, fatigue out of proportion to blood loss.
• Rh D-negative pregnant women, as part of standard antenatal antibody screening, and women with a previous affected pregnancy or previous transfusion.
• Newborns with jaundice appearing within the first 24 hours, rapidly rising bilirubin, or anaemia, particularly when the mother is Rh D-negative or blood group O.
• Patients who develop fever, rigors, back pain, dark urine or falling haemoglobin after a transfusion.
• People with autoimmune disease (such as lupus), chronic lymphocytic leukaemia, lymphoma, or after stem cell or organ transplantation, when anaemia develops.
• Patients on a drug known to be associated with immune haemolysis who develop unexplained anaemia.

The Coombs test is not a general health-check or screening test for the well population.

What the Coombs test cannot detect or exclude

• It does not measure haemolysis. A positive DCT tells you cells are antibody-coated, not that they are being destroyed, and not how fast. Haemoglobin, reticulocytes, LDH, indirect bilirubin and haptoglobin are needed for that.
• It does not exclude immune haemolysis when negative. Coombs-negative autoimmune haemolytic anaemia occurs, antibody levels may be below the method's detection threshold, or the antibody may be IgA or warm IgM, which standard reagents may not pick up.
• It says nothing about non-immune causes. Thalassaemia, sickle cell disease, G6PD deficiency, hereditary spherocytosis, malaria, mechanical valve haemolysis, snakebite and microangiopathy all cause haemolysis with a negative Coombs test.
• It does not identify the antibody. A positive ICT requires antibody identification panels to name the specificity (anti-D, anti-c, anti-K and so on).
• It does not predict fetal severity. A positive antenatal ICT does not tell you whether or how badly the fetus is affected; antibody titres, middle cerebral artery Doppler and specialist obstetric assessment are required.
• It does not diagnose lupus, rheumatoid arthritis or any autoimmune disease. Older patient material often overstates this. The Coombs test only indicates an immune process affecting red cells.

A negative result describes what the laboratory did not detect, not what is absent from the body. If symptoms persist despite a normal Coombs test, go back to the doctor who ordered it.

Related but different examinations

These tests answer different questions. Which is ordered first depends on the presentation: a jaundiced newborn of an Rh D-negative mother needs a DCT early; a young man from a thalassaemia-endemic district with lifelong anaemia needs a smear and HPLC first; a patient who deteriorates mid-transfusion needs an urgent post-transfusion DCT and clerical check.

How to prepare

• Fasting is not required for the Coombs test. If it is bundled with lipid or glucose tests, follow the fasting instruction for those.
• Bring transfusion history. Transfusions in the last three months, previous transfusion reactions, and any antibody card issued by a blood bank are important, carry the card if you have one.
• Bring pregnancy and obstetric history, including previous Rh immunoglobulin (anti-D) injections with dates, miscarriages, terminations, amniocentesis and previous affected babies.
• List all medicines and supplements, including recent antibiotics and any AYUSH or over-the-counter preparations. Do not stop or change any prescribed medicine to prepare for this test, speak to the prescriber first.
• Hydration generally makes venous access easier, unless your doctor has placed you on a fluid restriction.

Sample tube types, gel versus tube methodology, and whether the DCT is automatically extended to IgG and C3d typing vary between laboratories and blood banks. Your own laboratory's written instructions take precedence over any general guidance.

Pregnancy

The blood draw itself carries the same minor risks as any venipuncture. Timing of the antibody screen and of anti-D prophylaxis follows the antenatal protocol of the treating unit. Tell the laboratory if anti-D has recently been given, as it can make a later ICT positive.

Newborns and children

Cord blood or a heel-prick/venous sample is used in newborns. Sample volumes are kept small. Crying, bruising and a small puncture mark are common and settle.

Older adults and people with fragile veins

Bruising is more likely. Tell the phlebotomist about blood thinners so firmer, longer pressure can be applied after the draw.

What happens during the test and how long it takes

• Registration and identity check: name, group, hospital number. This step is critical in transfusion testing and is never skipped.
• Blood draw: a tourniquet, skin cleaning and a needle into an arm vein. One or two tubes are filled. The draw itself typically takes one to three minutes.
• Total time at the counter: usually under 5-10 minutes for an outpatient, longer if the department is busy or veins are difficult.
• Laboratory work: cells are washed, anti-human globulin is added, and agglutination is read manually or by an automated gel-card system. Positive results may be extended with monospecific IgG and C3d reagents, elution studies or antibody identification panels, which add time.

Reporting time depends on whether the test is routine, antenatal or urgent pre-transfusion work, and on the laboratory's workflow. Ask your laboratory when your report will be ready.

Understanding your Coombs test report

Reports are usually qualitative: positive or negative, sometimes with a grade of agglutination strength and the type of coating detected.

Direct Coombs test

Positive: antibody and/or complement is coating the red cells. Possible explanations include autoimmune haemolytic anaemia (warm or cold type), HDFN, a delayed or acute haemolytic transfusion reaction, drug-induced immune haemolysis, or an underlying lymphoproliferative or autoimmune condition. A positive DCT also occurs in people with no haemolysis at all, including some healthy blood donors and hospitalised patients.

Negative: no detectable coating. Immune haemolysis becomes less likely but is not excluded, and non-immune causes remain fully possible.

Indirect Coombs test

Positive: free red cell antibodies are present. In pregnancy this may indicate alloimmunisation requiring antibody identification, titration and fetal surveillance. Before transfusion it means compatible units must be specially selected, which can take longer to arrange.

Negative: no antibody detected by the method used. This does not rule out a later antibody response after a future transfusion or pregnancy.

Grading (such as 1+ to 4+) reflects the strength of agglutination seen by the technologist or read by the analyser. It is a semi-quantitative, method-dependent observation. A stronger grade does not automatically mean more severe illness, and patients frequently over-read these numbers. No Coombs result should be interpreted on its own, it must be read together with haemoglobin, reticulocyte count, smear, bilirubin, LDH and the clinical picture, by the doctor who requested the test.

When Coombs test results can be misleading

Falsely positive or clinically unimportant positives

• Recent anti-D immunoglobulin in pregnancy can produce a positive maternal ICT and a weakly positive neonatal DCT.
• Drugs such as methyldopa, some cephalosporins and penicillins, and piperacillin-tazobactam can coat cells or provoke antibodies.
• Intravenous immunoglobulin, anti-thymocyte globulin and some monoclonal antibody therapies (for example daratumumab) can interfere with antiglobulin testing.
• Recent transfusion leaves a mixed population of donor and patient cells, complicating interpretation.
• High plasma globulins: as in multiple myeloma, chronic infection or chronic liver disease, can cause non-specific positivity.
• Cold agglutinins and inadequate washing or delayed testing of the sample can generate spurious agglutination.

Falsely negative or weakly detected

• Low-density antibody coating below the method's detection limit, seen in some genuine autoimmune haemolytic anaemias.
• IgA or warm IgM antibodies, which standard polyspecific reagents may not detect.
• Prozone effect, over-washing of cells, or reagent quality and storage problems.
• Brisk haemolysis where the most heavily coated cells have already been destroyed and cleared.
• Clotted or old samples, or a sample taken in the wrong tube.

Because of these effects, discordant results are sometimes resolved by repeat testing, monospecific reagents, elution studies or referral to a reference immunohaematology laboratory.

Risks and safety

The blood draw

Risks are those of routine venipuncture: brief pain, bruising, light-headedness and, uncommonly, a small haematoma or local infection. Bruising is more likely on anticoagulants or antiplatelet drugs.

Newborn sampling

Cord blood sampling adds no risk to the baby. Heel-prick or venous sampling causes brief distress and occasional bruising.

Interpretation-related risk

The main risk of the Coombs test is not physical but interpretive, acting on a positive result without confirming that haemolysis is occurring, or stopping the search for a cause because a result was negative. Results vary depending on individual clinical circumstances.

Special situations

Pregnancy

The indirect Coombs test is the antenatal antibody screen. Rh D-negative women are screened and, where indicated, offered anti-D prophylaxis at defined points in pregnancy and after delivery, miscarriage, termination or abdominal trauma, per the unit's obstetric protocol. Keep records of every anti-D dose. A previously sensitised woman cannot be protected by anti-D, she needs specialist fetal medicine follow-up instead.

Newborns

A DCT on cord or neonatal blood helps explain early jaundice or anaemia. ABO incompatibility (mother O, baby A or B) often gives a weak or negative DCT despite genuine haemolysis, so bilirubin trends and the blood picture matter more than the DCT grade alone. Management may involve phototherapy, close bilirubin monitoring, intravenous immunoglobulin or exchange transfusion, as decided by the neonatal team.

Recently transfused patients

A DCT performed within days to weeks of transfusion may reflect donor cells and can be difficult to interpret. Tell the laboratory the date of the last transfusion.

People with autoimmune disease or blood cancers

Lupus, chronic lymphocytic leukaemia and lymphomas are associated with secondary autoimmune haemolytic anaemia. A positive DCT here prompts assessment of the underlying disease, not a separate diagnosis.

Older adults

Positive DCT results without haemolysis become more common with age, multiple medicines and hospitalisation. Interpretation must be cautious.

People on multiple medicines

Never stop a suspected drug on your own. Any decision to change or withdraw a medicine implicated in immune haemolysis belongs to the prescribing doctor.

The Coombs test in the Indian context

• Non-immune haemolysis is common. Beta-thalassaemia trait, sickle cell disease and G6PD deficiency are prevalent in several Indian populations. In these patients, the Coombs test is typically negative, and haemoglobin HPLC, G6PD assay and family history are the informative tests. A negative Coombs test in a child with chronic anaemia should push the work-up towards these conditions, not close it.
• Infections matter. Malaria, dengue and other acute infections can cause anaemia and jaundice with a negative Coombs test; some infections can also produce transient positivity.
• Antenatal practice. Rh D-negative status and antibody screening are standard parts of Indian antenatal booking investigations, and anti-D prophylaxis is widely available. Documented anti-D dates on the antenatal card prevent confusion when a later ICT is positive.
• Multiply transfused patients. Children and adults with thalassaemia who receive regular transfusions have a real risk of developing red cell alloantibodies, which makes antibody screening and extended matching important.
• Regulation and privacy. Blood banks and transfusion services in India operate under the Drugs and Cosmetics Rules and National Blood Transfusion Council standards. Any personal data collected through hospital forms or portals is handled under the Digital Personal Data Protection Act, 2023.

Cost and insurance in India

The Coombs test is an inexpensive blood test relative to imaging or molecular testing, but charges differ widely between government facilities, blood banks, standalone laboratories and corporate hospitals. Rather than quoting a figure, it is more useful to know what drives the price.

• Which test is ordered: a DCT alone costs less than a DCT plus monospecific IgG/C3d typing, elution and antibody identification panels.
• Method used: conventional tube technique is cheaper than automated gel-card or solid-phase systems.
• Urgency: emergency and after-hours processing often attracts a higher charge.
• Bundling: antenatal profiles and pre-transfusion workups usually include the antiglobulin test within a package price.
• Setting: government hospitals and public blood banks often provide the test free or at nominal cost; private accredited laboratories charge more.
• Insurance: the test is generally covered when performed during an admission or as part of a covered maternity or transfusion episode. Outpatient diagnostic tests are frequently not reimbursed unless the policy includes an OPD benefit. Confirm with your insurer or the hospital billing desk before testing.

Myths and facts

Frequently asked questions

What is the difference between the direct and indirect Coombs test?

The direct Coombs test examines the patient's own red cells for antibody or complement already attached to them. The indirect Coombs test examines plasma for free antibodies that could attack red cells later. The direct test is used in haemolysis and newborn jaundice; the indirect test in antenatal screening and transfusion compatibility.

Does a positive Coombs test always mean anaemia?

No. A positive direct Coombs test shows antibody coating on red cells, not that the cells are being destroyed. Some people with a positive result have completely normal haemoglobin. The treating doctor confirms whether haemolysis is actually occurring using reticulocyte count, LDH, bilirubin, haptoglobin and the peripheral smear.

Why is the ICT test done in pregnancy?

The indirect Coombs test screens for red cell antibodies that can cross the placenta and damage the baby's red cells, causing haemolytic disease of the fetus and newborn. Screening is particularly important in Rh D-negative women and in anyone previously transfused. A positive screen leads to antibody identification and specialist fetal monitoring.

Do I need to fast before a Coombs test?

Fasting is not required for the Coombs test. If the same blood draw includes fasting glucose or a lipid profile, follow the fasting instruction for those tests. Continue all prescribed medicines unless your own doctor has specifically told you otherwise, and list them for the laboratory.

Is the Coombs test painful?

The Coombs test involves an ordinary blood draw from an arm vein. Most people feel a brief sting during needle insertion and nothing afterwards. Mild soreness or a small bruise at the puncture site can last a day or two. Pressure over the site for a few minutes reduces bruising.

Can medicines cause a false-positive Coombs test?

Yes. Methyldopa, some penicillins and cephalosporins, piperacillin-tazobactam, intravenous immunoglobulin and certain monoclonal antibody therapies can produce positive antiglobulin results. Tell the laboratory and your doctor about every medicine and supplement. Do not stop any prescribed drug yourself, the prescriber decides whether a change is needed.

What happens if my newborn's Coombs test is positive?

A positive neonatal direct Coombs test suggests maternal antibodies are coating the baby's red cells. The neonatal team monitors bilirubin and haemoglobin closely. Treatment depends on severity and may involve phototherapy, close observation, intravenous immunoglobulin or, uncommonly, exchange transfusion. Many babies with a positive result need only monitoring.

Can the Coombs test detect thalassaemia or G6PD deficiency?

No. Thalassaemia, sickle cell disease and G6PD deficiency are non-immune causes of red cell breakdown and give a negative Coombs test. Haemoglobin HPLC or electrophoresis, G6PD enzyme assay, peripheral smear and family history are the appropriate investigations for these conditions, which are common in parts of India.

How long does the Coombs test take?

The blood draw itself usually takes under five to ten minutes, including registration. Laboratory processing is quicker for a simple qualitative result and longer when monospecific typing, elution or antibody identification panels are needed. Urgent pre-transfusion testing is prioritised. Ask your laboratory when your specific report will be available.

Sources

• AABB. Technical Manual, standards and methods for direct and indirect antiglobulin testing.
• British Society for Haematology. Guidelines on the management of autoimmune haemolytic anaemia and on pre-transfusion compatibility procedures.
• National Blood Transfusion Council / National AIDS Control Organisation, India, standards for blood transfusion services.
• Federation of Obstetric and Gynaecological Societies of India (FOGSI), good clinical practice recommendations on Rh-negative pregnancy and anti-D prophylaxis.
• Indian Academy of Paediatrics / National Neonatology Forum, guidance on neonatal hyperbilirubinaemia.